Last reviewed · How we verify
Comparator: loratadine
Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.
Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria.
At a glance
| Generic name | Comparator: loratadine |
|---|---|
| Sponsor | Organon and Co |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Loratadine competitively binds to peripheral H1 histamine receptors, preventing histamine from triggering allergic symptoms such as itching, sneezing, and urticaria. Its lipophilic structure and large molecular size limit blood-brain barrier penetration, resulting in minimal sedation compared to first-generation antihistamines. It is a non-sedating second-generation antihistamine used for symptomatic relief of allergic conditions.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic urticaria
Common side effects
- Headache
- Somnolence
- Fatigue
- Dry mouth
Key clinical trials
- Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis (PHASE3)
- Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED) (PHASE3)
- Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) (PHASE3)
- A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED) (PHASE3)
- Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235) (PHASE3)
- Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240) (PHASE3)
- A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (PHASE1)
- Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: loratadine CI brief — competitive landscape report
- Comparator: loratadine updates RSS · CI watch RSS
- Organon and Co portfolio CI